Live
- BJP slams Rahul Gandhi for renewing Veer Savarkar-bashing after Maha polls
- New Zealand study highlights online harm for eight-year-olds
- RG Kar tragedy: Former SHO of Tala PS moves Calcutta HC for bail
- World Boxing backs plan to create a new Confederation in Asia
- Shubham Nigam: Transforming SaaS Growth Marketing with AI
- Convert those starts: Hemp wants Bangladesh batters to score big in second Test vs West Indies
- Grand Pushpayagam Celebrated at Venkanna Temple
- MLA Kuchukulla Rajesh Reddy Inspects Markandeya Lift Irrigation Project
- Government Committed to Village Development: MLA Dr. Rajesh Reddy
- Scientists Awareness on Natural Farming for Farmers
Zydus gets USFDA nod for generic anti-pregnancy medication
Zydus Lifesciences on Friday said it has received final approval from the US health regulator to market a generic medication to prevent pregnancy.
Zydus Lifesciences on Friday said it has received final approval from the US health regulator to market a generic medication to prevent pregnancy.
The company has received final approval from the US Food and Drug Administration (USFDA) for Norelgestromin and Ethinyl Estradiol Transdermal System (150 mcg/35 mcg per day), the drug firm said in a statement.
Norelgestromin and Ethinyl Estradiol Transdermal System contains combination hormone medication and is used to prevent pregnancy.
The transdermal patch will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, Zydus Lifesciences said.
As per IQVIA MAT data, Norelgestromin and Ethinyl Estradiol Transdermal System (150 mcg/35 mcg) had annual sales of USD 330 million in the US market. Shares of the company settled 0.93 per cent up at Rs 645.65 apiece on the BSE.
